Exagen Diagnostics

General Information

We are a commercial-stage diagnostics company committed to addressing the significant unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. These chronic diseases can cause lifelong inflammation in the joints, tissues and internal organs, resulting in serious complications, such as irreversible organ damage. Untreated chronic inflammation can also lead to premature hardening of the arteries, heart attacks and strokes. The accurate, timely and differential diagnosis for patients suffering from the approximately 30 autoimmune rheumatic diseases, or ARDs, is critical as treatment for each disease can vary, and inappropriate or delayed therapy may expose patients to unnecessary risks or the hazards of uncontrolled disease activity. Physicians face significant difficulties in making a definitive diagnosis of a specific ARD because patients with different diseases often present with a common set of symptoms. We currently market four products under our Avise brand to provide an accurate, timely and differential diagnosis and to optimize the treatment of ARDs. We processed approximately 9,300 patient specimens for our lead diagnostic product line, Avise SLE, in 2013 and approximately 11,100 in the first six months of 2014.

Employees: 107
Founded: 2002
Contact Information
Address 1261 Liberty Way, Suite C, Vista, CA 92081, US
Phone Number (505) 272-7966
Web Address http://www.exagen.com
View Prospectus: Exagen Diagnostics
Financial Information
Market Cap
Revenues $17.9 mil (last 12 months)
Net Income $-21.3 mil (last 12 months)
IPO Profile
Symbol EXDX
Exchange NASDAQ
Shares (millions): 0.0
Price range $0.00 - $0.00
Est. $ Volume $69.0 mil
Manager / Joint Managers Leerink Partners/ Baird
CO-Managers William Blair
Expected To Trade:
Status: TBA
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change